1280 Participants Needed

STAR Program for Sepsis

(ASTROS Trial)

MK
Overseen ByMarc Kowalkowski, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Wake Forest University Health Sciences
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to evaluate how well the STAR (Sepsis Transition and Recovery) program aids recovery from sepsis after hospital discharge. Sepsis is a serious infection that can lead to organ failure, and the STAR program provides virtual support during the transition from hospital to home. Participants will either receive this specialized support or continue with the usual care provided by their hospitals. Individuals who have experienced a serious infection leading to hospitalization and are at risk of returning to the hospital soon may be suitable candidates. As an unphased trial, this study offers a unique opportunity to contribute to understanding the role of virtual support in sepsis recovery.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the STAR Program is safe for sepsis patients?

Research has shown that the Sepsis Transition and Recovery (STAR) program is generally well-received by participants. One study found that this program, which offers virtual support after a hospital stay for sepsis, helps people live longer. It significantly reduced deaths within 30 and 90 days after leaving the hospital. This suggests the program is likely safe, as better survival rates usually indicate fewer serious side effects. Another study confirmed that the STAR program lowers the risk of dying soon after hospital discharge. Reports of major negative effects were absent, which is a positive sign for safety. Overall, the STAR program seems to be a safe choice for those recovering from sepsis.12345

Why are researchers excited about this trial?

The STAR Program for sepsis is unique because it offers a virtual sepsis navigation system that supports patients during the critical transition period from hospital to home. Unlike the standard care, which varies by facility and is determined by individual clinicians, the STAR Program provides a consistent and structured approach to managing recovery. Researchers are excited about this trial because it could improve patient outcomes by ensuring continuity of care and reducing the risk of complications after discharge. This innovative method leverages technology to provide personalized support, potentially transforming the recovery process for sepsis patients.

What evidence suggests that the STAR Program is effective for enhancing post sepsis outcomes?

Research has shown that the Sepsis Transition and Recovery (STAR) program, which participants in this trial may receive, can significantly aid sepsis recovery. Studies have found that patients in the STAR program had lower chances of dying or being readmitted to the hospital within 30 days compared to those who received usual care, another treatment arm in this trial. One study also found that the program reduced the risk of dying within 90 days. The STAR program includes a nurse who guides patients and uses telehealth, providing remote healthcare to support recovery. This approach has successfully improved long-term health for sepsis survivors.13467

Who Is on the Research Team?

MA

Marc A. Kowalkowski, PhD

Principal Investigator

Wake Forest University Health Sciences

SB

Sarah Birken, PhD

Principal Investigator

Wake Forest University Health Sciences

Are You a Good Fit for This Trial?

This trial is for adults over 18 with suspected infection and signs of systemic inflammation, who've started antibiotics within 24 hours that continued for at least another day. They must have organ dysfunction indicated by SOFA scores or be at high risk of hospital readmission within 90 days.

Inclusion Criteria

You present with two or more symptoms of systemic inflammatory response syndrome within 24 hours.
My organs are not functioning well according to a recent assessment.
I started antibiotics within a day and took them for at least another day.
See 8 more

Exclusion Criteria

Actively participating in a different care management program documented in the electronic health record (EHR) at time of hospital admission
My treatment plan was changed within 24 hours of my initial assessment due to limitations in aggressive treatment and exposure to the STAR program.
I live more than 2.5 hours away from the hospital by car.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-implementation

Qualitative evaluation to identify core functions necessary to maintain program effectiveness when implementing the STAR program in new settings

Varies

Treatment

Participants receive the Sepsis Transition and Recovery (STAR) program intervention, a 90-day, nurse-navigator-led program designed to facilitate transition/recovery after sepsis hospitalization

90 days
Virtual visits across the peri-hospital discharge interval

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of mortality and hospital readmission rates

90 days

What Are the Treatments Tested in This Trial?

Interventions

  • STAR Program
  • Usual Care
Trial Overview The ASTROS study is testing the STAR Program against usual care to see if it improves recovery after sepsis in new hospital settings. It uses a multiple interrupted time series analysis to measure effectiveness as hospitals adopt the program.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Sepsis Transition and Recovery (STAR) programExperimental Treatment1 Intervention
Group II: Usual CareActive Control1 Intervention

STAR Program is already approved in United States for the following indications:

🇺🇸
Approved in United States as Sepsis Transition and Recovery Program for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials
1,432
Recruited
2,506,000+

The Duke Endowment

Collaborator

Trials
17
Recruited
48,100+

Published Research Related to This Trial

Implementing a proactive telehealth follow-up system for geriatric patients at the Tennessee Valley Healthcare System led to a significant reduction in 30-day all-cause readmissions, decreasing from 21% to 13% during the intervention period.
The use of Plan, Do, Study, Act (PDSA) cycles and data sharing among care teams improved care coordination and accountability, contributing to better management of high-risk patients.
The GeriPACT Initiative to Prevent All-Cause 30-Day Readmission in High Risk Elderly.Powers, JS., Abraham, L., Parker, R., et al.[2021]
The COMPASS Study is a large pragmatic randomized-controlled trial that aims to compare a patient-centered transitional care intervention with usual care for stroke patients, focusing on outcomes like functional status and caregiver strain 90 days post-discharge.
The study emphasizes robust stakeholder engagement, involving patients, caregivers, and community stakeholders, to enhance the effectiveness of the trial and address gaps in existing literature on stakeholder involvement in pragmatic research.
Methods guiding stakeholder engagement in planning a pragmatic study on changing stroke systems of care.Gesell, SB., Klein, KP., Halladay, J., et al.[2020]
The STAR program, a telehealth-based strategy for sepsis survivors, aims to improve post-discharge outcomes by providing proactive care coordination and monitoring, with a planned enrollment of 4032 patients over 36 months.
This study will evaluate the effectiveness of STAR in reducing hospital readmissions and mortality within 90 days of discharge, while also examining factors that influence its implementation across eight hospitals in North Carolina.
Protocol for a two-arm pragmatic stepped-wedge hybrid effectiveness-implementation trial evaluating Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship (ENCOMPASS).Kowalkowski, M., Eaton, T., McWilliams, A., et al.[2023]

Citations

Effect of a Multicomponent Sepsis Transition and Recovery ...A nurse navigator-led, multicomponent Sepsis Transition And Recovery program improves 30-day mortality and readmission outcomes after sepsis hospitalization.
Proactive Telehealth-Based Sepsis Transition and ...Objective To evaluate the effect of a sepsis transition and recovery (STAR) program compared with usual care on postdischarge outcomes.
Effectiveness of targeted post-acute interventions and follow ...In total, seven studies evaluated the effect of care coordination and bundle approaches on sepsis long-term outcome including 171,550 patients.
Sepsis recovery program saves lives but doesn't prevent ...When the outcomes were examined separately, however, the study found a significant drop in deaths among STAR participants. The 90-day mortality ...
Leveraging inter-organizational networks to scale up a sepsis ...We demonstrated improved outcomes following discharge among sepsis survivors who participated in the Sepsis Transition And Recovery (STAR) ...
Sepsis Transition and Recovery (STAR) program ...This systematic review aims to compile the present evidence on the effectiveness of post-acute interventions and follow-up services on patient-relevant long- ...
Protocol for a two-arm pragmatic stepped-wedge hybrid ...We developed the Sepsis Transition and Recovery (STAR) program to address persistent morbidity and mortality for sepsis survivors. The STAR ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security